Polyclonal Antibody to HDAC4/HDAC5/HDAC9 (phospho-Ser246/259/220)
Figure 1: Western blot analysis of extracts from 293 cells untreated or treated with EGF using HDAC4/HDAC5/HDAC9(phospho-Ser246/259/220) Antibody 35-1312 .
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
Format : | Purified |
Amount : | 100 µl |
Isotype : | Rabbit IgG |
Content : | Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
Storage condition : | Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles. |
Gene : | HDAC4 |
Gene ID : | 9759 |
Uniprot ID : | P56524 /Q9UQL6 Q |
Alternative Name : | HD4/HD5/HD9 |
Immunogen Information : | Peptide sequence around phosphorylation site of serine 246/259/220 (T-A-S(p)-EP) derived from Human HDAC4/HDAC5/HDAC9. |
Histone Deacetylases (HDACs) are a group of enzymes closely related to sirtuins. They catalyze the removal of acetyl groups from lysine residues in histones and non-histone proteins, resulting in transcriptional repression. In general,they do not act autonomously but as components of large multiprotein complexes, such as pRb-E2F and mSin3A, that mediate important transcription regulatory pathways. There are three classes of HDACs; classes 1, 2 and 4, which are closely related Zn2+-dependent enzymes. HDACs are ubiquitously expressed and they can exist in the nucleus or cytosol. Their subcellular localization is effected by protein-protein interactions (for example HDAC-14.3.3 complexes are retained in the cytosol) and by the class to which they belong (class 1 HDACs are predominantly nuclear whilst class 2 HDACs shuttle between the nucleus and cytosol). HDACs have a role in cell growth arrest, differentiation and death and this has led to substantial interest in HDAC inhibitors as possible antineoplastic agents.
Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.
Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.
Predicted MW: 140 124 111 kd, Western blotting: 1:500~1:1000, Immunohistochemistry: 1:50~1:100
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews
|